News
NEUWERK advises Secarna Pharmaceuticals on collaboration and option agreement with Protalix BioTherapeutics
12 January 2026
Secarna Pharmaceuticals GmbH & Co. KG announced on 17 December 2025 that it has entered into a collaboration and option agreement with Protalix BioTherapeutics, Inc. (NASDAQ: PLX).
The agreement relates to the joint discovery and development of novel antisense oligonucleotide therapies for the treatment of rare kidney diseases. Secarna contributes its proprietary, AI-enabled OligoCreator® platform for the identification and optimisation of drug candidates. Protalix receives an exclusive, worldwide option to license selected programmes for further development and commercialisation. The agreement provides for milestone payments and royalty-based compensation and aims to advance preclinical programmes into clinical development.
NEUWERK advised Secarna Pharmaceuticals comprehensively on the structuring and negotiation of the collaboration and option agreement.
About Secarna Pharmaceuticals:
Secarna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative oligonucleotide therapies for diseases with high unmet medical need.
The NEUWERK team: